Magazine article from our research archive:

Drug trial data is just the tonic for Glaxo.

News that Novartis' new diabetes product, Galvus, has disappointed in the clinic is a shot in the arm for GlaxoSmithKline (GSK). The drug is a potential rival to GSK's Avandia. But two-year trial data released this week shows that Galvus is not as effective as metformin, the industry-standard drug, in cutting ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!